| __timestamp | BioCryst Pharmaceuticals, Inc. | BioMarin Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7461000 | 302156000 |
| Thursday, January 1, 2015 | 13047000 | 402271000 |
| Friday, January 1, 2016 | 11253000 | 476593000 |
| Sunday, January 1, 2017 | 13933000 | 554336000 |
| Monday, January 1, 2018 | 29514000 | 604353000 |
| Tuesday, January 1, 2019 | 37121000 | 680924000 |
| Wednesday, January 1, 2020 | 67929000 | 737669000 |
| Friday, January 1, 2021 | 118818000 | 759375000 |
| Saturday, January 1, 2022 | 159371000 | 854009000 |
| Sunday, January 1, 2023 | 213894000 | 937300000 |
| Monday, January 1, 2024 | 1009025000 |
Infusing magic into the data realm
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining financial health. BioMarin Pharmaceutical Inc. and BioCryst Pharmaceuticals, Inc. have shown contrasting trends in their SG&A expenses from 2014 to 2023. BioMarin's expenses have consistently been higher, peaking at approximately $937 million in 2023, reflecting a steady growth of around 210% over the decade. In contrast, BioCryst's expenses, while significantly lower, have surged by nearly 280%, reaching about $214 million in 2023. This divergence highlights BioMarin's expansive operational scale compared to BioCryst's more conservative approach. Understanding these trends offers insights into each company's strategic priorities and market positioning. As the biotech industry evolves, monitoring such financial metrics will be key to predicting future growth trajectories.
Breaking Down SG&A Expenses: Zoetis Inc. vs BioCryst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Alnylam Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for BioMarin Pharmaceutical Inc. and Walgreens Boots Alliance, Inc.
Breaking Down SG&A Expenses: BioMarin Pharmaceutical Inc. vs TG Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and Rhythm Pharmaceuticals, Inc.
BioMarin Pharmaceutical Inc. vs BioCryst Pharmaceuticals, Inc.: Examining Key Revenue Metrics
Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs Novavax, Inc. Trends and Insights
Analyzing R&D Budgets: BioMarin Pharmaceutical Inc. vs BioCryst Pharmaceuticals, Inc.
Jazz Pharmaceuticals plc vs BioCryst Pharmaceuticals, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Opthea Limited and BioCryst Pharmaceuticals, Inc.
MorphoSys AG vs BioCryst Pharmaceuticals, Inc.: SG&A Expense Trends
Supernus Pharmaceuticals, Inc. vs BioCryst Pharmaceuticals, Inc.: SG&A Expense Trends